- Home
- SOWG vs KALA Comparison
SOWG vs KALA Comparison
Compare SOWG & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- KALA
- Stock Information
- Founded
- SOWG 2010
- KALA 2009
- Country
- SOWG United States
- KALA United States
- Employees
- SOWG N/A
- KALA N/A
- Industry
- SOWG Packaged Foods
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- KALA Health Care
- Exchange
- SOWG Nasdaq
- KALA Nasdaq
- Market Cap
- SOWG 23.1M
- KALA 27.3M
- IPO Year
- SOWG N/A
- KALA 2017
- Fundamental
- Price
- SOWG $2.35
- KALA $6.94
- Analyst Decision
- SOWG Strong Buy
- KALA Strong Buy
- Analyst Count
- SOWG 2
- KALA 2
- Target Price
- SOWG $23.00
- KALA $15.00
- AVG Volume (30 Days)
- SOWG 143.2K
- KALA 27.8K
- Earning Date
- SOWG 02-20-2025
- KALA 11-12-2024
- Dividend Yield
- SOWG N/A
- KALA N/A
- EPS Growth
- SOWG N/A
- KALA N/A
- EPS
- SOWG 0.21
- KALA N/A
- Revenue
- SOWG $40,130,971.00
- KALA N/A
- Revenue This Year
- SOWG $122.17
- KALA N/A
- Revenue Next Year
- SOWG N/A
- KALA N/A
- P/E Ratio
- SOWG $11.20
- KALA N/A
- Revenue Growth
- SOWG 508.45
- KALA N/A
- 52 Week Low
- SOWG $2.10
- KALA $4.21
- 52 Week High
- SOWG $24.83
- KALA $9.25
- Technical
- Relative Strength Index (RSI)
- SOWG 19.54
- KALA 59.76
- Support Level
- SOWG $2.10
- KALA $5.67
- Resistance Level
- SOWG $2.51
- KALA $6.04
- Average True Range (ATR)
- SOWG 0.20
- KALA 0.34
- MACD
- SOWG 0.19
- KALA 0.03
- Stochastic Oscillator
- SOWG 25.25
- KALA 76.67
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free granola products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.